Distinguished keynote speakers included Dr. Lorne Babiuk, University of Alberta, Dr. Greg Poland, Mayo Clinic, and Dr. Rino Rappuoli, GSK together with many of Canada’s top vaccine researchers. Vaccine research and development in Canada, bacterial vaccines, viral vaccines, formulations, delivery and bioprocessing were topics to identify strengths and gaps in the Canadian vaccine landscape.
Check out the final program from 2015
Presentations from 2015 Conference
Strengths and Gaps in the Canadian Vaccine Landscape: a biotech perspective
Nathalie Charland, PhD Medicago
Development of RSV Vaccines
Ann-Muriel Steff, PhD GSK
Development of Advanced Adjuvants and Immune Modulators
R.E.W (Bob) Hancock, University of British Columbia
Canadian Contribution to Vaccine Adjuvant R&D
David Burt, GSK
Emerging of the first novel Canadian adjuvant and its potential
Denis Leclerc, Folia Biotech
Formulations, Delivery and Bioprocessing
Jim Richards, NRC
Vaccination: Canada’s leadership over the last century
Lorne A. Babiuk, University of Alberta
Hepatitis C Vaccines
Michael Houghton, University of Alberta
Can we eliminate important bacterial pathogens with protein-based vaccines?
Dr. Tony Schryvers, University of Calgary
